Literature DB >> 12228154

Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro.

R L Van Bezooijen1, L Van Der Wee-Pals, S E Papapoulos, C W G M Löwik.   

Abstract

BACKGROUND: Interleukin 17 (IL17) is produced by activated T cells and has been implicated in the development of bone lesions and cartilage degradation in rheumatoid arthritis (RA).
OBJECTIVE: To determine whether IL17, alone or together with tumour necrosis factor alpha (TNFalpha), induces cartilage destruction in vitro.
METHODS: Fetal mouse metatarsals stripped of endogenous osteoclast precursors were used to study the effect of IL17 on cartilage degradation independently of osteoclastic resorption. Cartilage destruction was analysed histologically by Alcian blue staining.
RESULTS: IL17 alone, up to 100 ng/ml, had no effect on the cartilage of fetal mouse metatarsals. IL17 (>/=0.1 ng/ml), however, induced severe cartilage degradation when given together with TNFalpha (>/=1 ng/ml). The cytokine combination decreased Alcian blue staining, a marker of proteoglycans, throughout the metatarsals and induced loss of the proliferating and early hypertrophic chondrocyte zones. TNFalpha alone also decreased Alcian blue staining, but not as dramatically as the cytokine combination. In addition, it did not induce loss of chondrocyte zones. Treatment with inhibitors of matrix metalloproteinase (MMP) activity and nitric oxide synthesis showed that MMP activity played a part in cartilage degradation, whereas nitric oxide production did not.
CONCLUSIONS: IL17, together with TNFalpha, induced cartilage degradation in fetal mouse metatarsals in vitro. IL17 may, therefore, participate in the development of cartilage destruction associated with RA by enhancing the effects of TNFalpha and may provide a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12228154      PMCID: PMC1753923          DOI: 10.1136/ard.61.10.870

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  44 in total

Review 1.  Matrix metalloproteinase inhibitors in rheumatic diseases.

Authors:  D R Close
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo.

Authors:  L Cai; J P Yin; M A Starovasnik; D A Hogue; K J Hillan; J S Mort; E H Filvaroff
Journal:  Cytokine       Date:  2001-10-07       Impact factor: 3.861

3.  Potent collagenase inhibitors prevent interleukin-1-induced cartilage degradation in vitro.

Authors:  J S Nixon; K M Bottomley; M J Broadhurst; P A Brown; W H Johnson; G Lawton; J Marley; A D Sedgwick; S E Wilkinson
Journal:  Int J Tissue React       Date:  1991

4.  High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients.

Authors:  M C Honorati; R Meliconi; L Pulsatelli; S Canè; L Frizziero; A Facchini
Journal:  Rheumatology (Oxford)       Date:  2001-05       Impact factor: 7.580

Review 5.  Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001).

Authors:  D E Furst; E C Keystone; F C Breedveld; J R Kalden; J S Smolen; C E Antoni; G R Burmester; L J Crofford; A Kavanaugh
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

6.  The prevention of collagen breakdown in bovine nasal cartilage by TIMP, TIMP-2 and a low molecular weight synthetic inhibitor.

Authors:  A J Ellis; V A Curry; E K Powell; T E Cawston
Journal:  Biochem Biophys Res Commun       Date:  1994-05-30       Impact factor: 3.575

7.  Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption.

Authors:  C W Löwik; P H Nibbering; M van de Ruit; S E Papapoulos
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

8.  In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes.

Authors:  E H Burger; J W Van der Meer; J S van de Gevel; J C Gribnau; G W Thesingh; R van Furth
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

9.  IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis.

Authors:  M Chabaud; E Lubberts; L Joosten; W van Den Berg; P Miossec
Journal:  Arthritis Res       Date:  2001-01-26

10.  Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones.

Authors:  L Blavier; J M Delaissé
Journal:  J Cell Sci       Date:  1995-12       Impact factor: 5.285

View more
  30 in total

1.  Effects of TNF inhibitor on innate inflammatory and Th17 cytokines in stimulated whole blood from rheumatoid arthritis patients.

Authors:  Sladjana Zivojinovic; Nada Pejnovic; Mirjana Sefik-Bukilica; Ljiljana Kovacevic; Ivan Soldatovic; Diana Bugarski; Slavko Mojsilovic; Nemanja Damjanov
Journal:  Inflammopharmacology       Date:  2012-06-24       Impact factor: 4.473

Review 2.  Regulation and function of IL-17A- and IL-22-producing γδ T cells.

Authors:  Kristin J Ness-Schwickerath; Craig T Morita
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.261

Review 3.  Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis.

Authors:  M I Koenders; L A B Joosten; W B van den Berg
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

4.  Pathologic finding of increased expression of interleukin-17 in the synovial tissue of rheumatoid arthritis patients.

Authors:  Ning Li; Jun C Wang; Toong H Liang; Ming H Zhu; Jia Y Wang; Xue L Fu; Jie R Zhou; Song G Zheng; Paul Chan; Jie Han
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

5.  Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.

Authors:  Marije I Koenders; Erik Lubberts; Birgitte Oppers-Walgreen; Liduine van den Bersselaar; Monique M Helsen; Franco E Di Padova; Annemieke M H Boots; Hermann Gram; Leo A B Joosten; Wim B van den Berg
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

6.  Nitric oxide enhances aggrecan degradation by aggrecanase in response to TNF-alpha but not IL-1beta treatment at a post-transcriptional level in bovine cartilage explants.

Authors:  A L Stevens; C A Wheeler; S R Tannenbaum; A J Grodzinsky
Journal:  Osteoarthritis Cartilage       Date:  2007-10-10       Impact factor: 6.576

Review 7.  The role of T helper type 17 cells in inflammatory arthritis.

Authors:  S Sarkar; L A Cooney; D A Fox
Journal:  Clin Exp Immunol       Date:  2009-08-25       Impact factor: 4.330

8.  Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti-TNF-α therapy.

Authors:  Li Xueyi; Chen Lina; Wu Zhenbiao; Han Qing; Li Qiang; Ping Zhu
Journal:  J Clin Immunol       Date:  2012-08-29       Impact factor: 8.317

Review 9.  Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis.

Authors:  Bruce W Kirkham; Arthur Kavanaugh; Kristian Reich
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

10.  Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.

Authors:  Ellen M Moran; Ronan Mullan; Jennifer McCormick; Mary Connolly; Owen Sullivan; Oliver Fitzgerald; Barry Bresnihan; Douglas J Veale; Ursula Fearon
Journal:  Arthritis Res Ther       Date:  2009-07-23       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.